Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering